Clinical trials in Malaga – page 83

1 063 clinical trials in Malaga, Spain across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in SpainEnsayosClinicos.es

Malaga at a glance

1 063

clinical trials

Research sites4

Quick filters

1 063 trials in Malaga

Open in trial search

Follicular lymphoma+1

Not recruiting

Study of Tafasitamab, Lenalidomide, and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma

Registered drug

Study of Tafasitamab, Lenalidomide, and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Lenalidomide
Sponsor:Incyte Corp.

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Study Comparing SB27 and Pembrolizumab for Patients with Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo

Study Comparing SB27 and Pembrolizumab for Patients with Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Samsung Bioepis Co. Ltd.

Contact Research Centre

Non-small cell lung cancer stage IV+1

Not recruiting

Study of BMS-986315 and Nivolumab with Chemotherapy for First-line Treatment in Stage IV or Recurrent Non-Small Cell Lung Cancer Patients

Registered drugNo placebo

Study of BMS-986315 and Nivolumab with Chemotherapy for First-line Treatment in Stage IV or Recurrent Non-Small Cell Lung Cancer Patients

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:BMS-986315
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Hormone receptor positive breast cancer+1

Not recruiting

Study of Giredestrant Combined with Pertuzumab-Trastuzumab (Phesgo) for Patients with Previously Untreated HER2-Positive, Estrogen Receptor-Positive Locally Advanced or Metastatic Breast Cancer

Registered drugNo placebo

Study of Giredestrant Combined with Pertuzumab-Trastuzumab (Phesgo) for Patients with Previously Untreated HER2-Positive, Estrogen Receptor-Positive Locally Advanced or Metastatic Breast Cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Anastrozole
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Monkeypox

Not recruiting

Study on Monkeypox Virus Disease: Effects of Tecovirimat in Patients with and without Antiviral Treatment

Registered drugNo placebo

Study on Monkeypox Virus Disease: Effects of Tecovirimat in Patients with and without Antiviral Treatment

Registered drugNo placebo

Spain

Participants:0–17 years · 18–64 years · 65+ years
Substances:Tecovirimat
Sponsor:University Of Oxford

Contact Research Centre

Metabolic dysfunction-associated steatohepatitis+1

Not recruiting

Study on the Safety and Effects of AZD4831 for Adults with Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH) with Fibrosis

Investigational

Study on the Safety and Effects of AZD4831 for Adults with Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH) with Fibrosis

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:AZD4831
Sponsor:AstraZeneca AB

Contact Research Centre

Infertility female+1

Not recruiting

Study on Ovarian Response in Women with Infertility Using Follitropin Delta and Menotrophin During Assisted Reproductive Technology

Registered drugNo placebo

Study on Ovarian Response in Women with Infertility Using Follitropin Delta and Menotrophin During Assisted Reproductive Technology

Registered drugNo placebo

Spain

Participants:18–64 years
Substances:Follitropin Delta
Sponsor:Ferring Pharmaceuticals A/S

Contact Research Centre

Plasma cell myeloma

Not recruiting

Study to Compare Mezigdomide, Carfilzomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo

Study to Compare Mezigdomide, Carfilzomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Carfilzomib
Sponsor:Celgene Corp.

Contact Research Centre

Hormone-refractory prostate cancer

Not recruiting

Study Comparing [177Lu]LU-PSMA-I&T and Hormone Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo

Study Comparing [177Lu]LU-PSMA-I&T and Hormone Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Abiraterone Acetate
Sponsor:Curium Pet France

Contact Research Centre

Renal cell carcinoma

Not recruiting

Study on the Safety and Effectiveness of Pembrolizumab for Patients with Kidney Cancer After Surgery

Registered drug

Study on the Safety and Effectiveness of Pembrolizumab for Patients with Kidney Cancer After Surgery

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Squamous cell carcinoma

Not recruiting

Study of Pembrolizumab as Additional Treatment for Patients with High-Risk Locally Advanced Cutaneous Squamous Cell Carcinoma After Surgery and Radiation

Registered drug

Study of Pembrolizumab as Additional Treatment for Patients with High-Risk Locally Advanced Cutaneous Squamous Cell Carcinoma After Surgery and Radiation

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Hormone-refractory prostate cancer+1

Not recruiting

Study of Pembrolizumab and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drug

Study of Pembrolizumab and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Enzalutamide
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Malaga

What the registry says about research in the country

01 Autoimmune Conditions

Research focusing on innovative treatments for cutaneous lupus erythematosus and myasthenia gravis, evaluating new therapeutic approaches to improve patient outcomes.

Lupus skin manifestations
Neuromuscular disorders
Chronic urticaria management

Studies aim to assess novel therapies' effectiveness in reducing disease activity and improving daily living activities.

02 Infectious Diseases

Innovative vaccine development studies targeting COVID-19, cytomegalovirus, and respiratory syncytial virus, focusing on prevention and immune response.

Viral infections
Vaccine combinations
Pediatric prevention

Research emphasizes safety and immunogenicity in various population groups.

03 Oncology

Advanced studies in bladder cancer, colorectal cancer, and gastric cancer, evaluating targeted therapies and combination treatments.

Non-muscle invasive treatments
Metastatic disease management
Immunotherapy approaches

Trials focus on improving survival rates and treatment responses in various cancer types.

04 Respiratory Medicine

Research examining new treatments for chronic rhinosinusitis and COPD, with emphasis on symptom management and exacerbation prevention.

Airway inflammation
Pulmonary function
Quality of life measures

Studies evaluate novel therapeutic approaches for chronic respiratory conditions.

Back to Spain All countries